AbbVie Inc. Sample Contracts

AbbVie Inc. – PRESS RELEASE (January 25th, 2019)

Delivers Full-Year Net Revenues of $32.753 Billion on a GAAP Basis; Adjusted Net Revenues of $32.733 Billion Increased 15.2 Percent on an Operational Basis

AbbVie Inc. – PRESS RELEASE AbbVie Announces Executive Leadership Changes (December 17th, 2018)

NORTH CHICAGO, Ill., Dec. 17, 2018 — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its long-term growth strategy.  Effective immediately, the new Team will consist of the following individuals, all of whom report to AbbVie Chairman and Chief Executive Officer Richard A. Gonzalez:

AbbVie Inc. – PRESS RELEASE (November 2nd, 2018)

Delivers Third-Quarter Net Revenues of $8.236 Billion on a GAAP Basis; Adjusted Net Revenues of $8.236 Billion Increased 18.5 Percent on an Operational Basis

AbbVie Inc. – ABBVIE INC. $1,250,000,000 3.375% Senior Notes due 2021 $1,250,000,000 3.750% Senior Notes due 2023 $1,750,000,000 4.250% Senior Notes due 2028 $1,750,000,000 4.875% Senior Notes due 2048 UNDERWRITING AGREEMENT (September 18th, 2018)
AbbVie Inc. – ABBVIE INC. SUPPLEMENTAL INDENTURE NO. 5 $1,250,000,000 3.375% Senior Notes due 2021 $1,250,000,000 3.750% Senior Notes due 2023 $1,750,000,000 4.250% Senior Notes due 2028 $1,750,000,000 4.875% Senior Notes due 2048 (September 18th, 2018)

THIS SUPPLEMENTAL INDENTURE NO. 5, dated as of September 18, 2018 (the “Supplemental Indenture”), among ABBVIE INC., a Delaware corporation (the “Company”), and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”).

AbbVie Inc. – Contract (September 6th, 2018)

This FIRST AMENDMENT, dated as of August 31, 2018 (this “Amendment Agreement”), to that certain 364-Day Term Loan Credit Agreement, dated as of May 17, 2018 (as amended from time to time prior to the date hereof, the “Existing Credit Agreement”; and the Existing Credit Agreement as amended by the Amendments (as defined below), the “Amended Credit Agreement”), by and among AbbVie Inc., as Borrower (the “Borrower”), the lenders party thereto (the “Lenders”), and Bank of America, N.A., as administrative agent (the “Administrative Agent”), is made by and among the Borrower, the Lenders and the Administrative Agent.  Unless otherwise defined herein, terms defined in the Amended Credit Agreement and used herein shall have the meanings given to them in the Amended Credit Agreement.

AbbVie Inc. – REVOLVING CREDIT AGREEMENT Dated as of August 31, 2018 among ABBVIE INC., as Borrower, VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and JPMORGAN CHASE BANK, N.A. as Administrative Agent BANK OF AMERICA, N.A. and MORGAN STANLEY SENIOR FUNDING, INC. as Syndication Agents JPMORGAN CHASE BANK, N.A., MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED and MORGAN STANLEY SENIOR FUNDING, INC. as Joint Lead Arrangers and Bookrunners (September 6th, 2018)

This Revolving Credit Agreement (this “Agreement”) dated as of August 31, 2018 is among AbbVie Inc., a corporation organized and existing under the laws of the State of Delaware (the “Borrower”), the Lenders (as defined below) that are parties hereto, and JPMorgan Chase Bank, N.A., as administrative agent (together with any successor thereto appointed pursuant to Article VII, and including any applicable designated Affiliate, the “Administrative Agent”) for the Lenders.

AbbVie Inc. – PRESS RELEASE (July 27th, 2018)

Delivers Second-Quarter Net Revenues of $8.278 Billion on a GAAP Basis; Adjusted Net Revenues of $8.258 Billion Increased 17.1 Percent on an Operational Basis

AbbVie Inc. – 364-DAY TERM LOAN CREDIT AGREEMENT Dated as of May 17, 2018 among ABBVIE INC., as Borrower, VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and BANK OF AMERICA, N.A. as Administrative Agent JPMORGAN CHASE BANK, N.A. as Syndication Agent (May 18th, 2018)
AbbVie Inc. – ABBVIE INC. NON-EMPLOYEE DIRECTOR RESTRICTED STOCK UNIT AGREEMENT (May 4th, 2018)

On this «Grant_Day» day of «Grant_Month», 2018 (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name» (the “Director”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on a specified Delivery Date.

AbbVie Inc. – ABBVIE INC. NON-EMPLOYEE DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT (May 4th, 2018)

On this «Grant_Day» day of «Grant_Month», 2018 (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name», (the “Director”) an Option (the “Option”) to purchase a total of «NQSOs» Shares, at the price of $«Option_Price» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Market Value of the Shares on the Grant Date.

AbbVie Inc. – PERFORMANCE SHARE AWARD AGREEMENT (May 4th, 2018)

On this «Grant_Day» day of «Grant_Month», 2018 (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Share Award (the “Award”) of «NoShares12345» performance share units (the “Units”). The actual number of shares of Company common stock (the “Shares”) that may be issued under this Award will be determined in accordance with this Agreement by reference to the number of Units set forth above.

AbbVie Inc. – ABBVIE INC. NON-QUALIFIED STOCK OPTION AGREEMENT (May 4th, 2018)

On this «Grant_Day» day of «Grant_Month», 2018 (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name» (the “Employee”) an Option (the “Option”) to purchase a total of «NQSOs» Shares, at the price of $«Option_Price» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Market Value of the Shares on the Grant Date.

AbbVie Inc. – PERFORMANCE-VESTED RESTRICTED STOCK UNIT AGREEMENT (May 4th, 2018)

On this «Grant_Day» day of «Grant_Month», 2018 (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance-Vested Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”). The actual number of shares of Company common stock (the “Shares”) that may be issued under this Award will be determined in accordance with this Agreement by reference to the number of Units set forth above.

AbbVie Inc. – NOTICE TO DIRECTORS AND EXECUTIVE OFFICERS OF ABBVIE INC. REGARDING THE POTENTIAL COMPLETE BLACKOUT IN TRANSACTIONS INVOLVING EQUITY SECURITIES OF ABBVIE INC. (May 1st, 2018)

This notice is required by law and is to formally notify you of a possible complete blackout. Please note that the possible blackout referenced in this notice is in addition to any other blackout period to which you are otherwise subject, including the restrictions on trading activity under the AbbVie Insider Trading in Securities policy and any other relevant restrictions under tender offer rules.

AbbVie Inc. – PRESS RELEASE (April 26th, 2018)

Worldwide net revenues were $7.934 billion in the first quarter, up 21.4 percent year-over-year on a GAAP basis. On an operational basis, net revenues increased 17.6 percent, excluding a 3.8 percent favorable impact from foreign exchange.

AbbVie Inc. – ABBVIE NON-EMPLOYEE DIRECTORS’ FEE PLAN (February 16th, 2018)

This AbbVie Non-Employee Directors’ Fee Plan (the “Plan”) is maintained by AbbVie Inc. (the “Company”) to attract and retain as members of its Board of Directors persons who are not full-time employees of the Company or any of its subsidiaries but whose business experience and judgment are valuable assets to the Company and its subsidiaries. The Plan was originally adopted by the Company effective January 1, 2013, and it was amended and restated effective as of May 6, 2016. The terms of the Plan set forth in this document shall be effective as of May 4, 2018 (the “Effective Date”).

AbbVie Inc. – PERFORMANCE SHARE AWARD AGREEMENT (February 16th, 2018)

On this __ day of _________, 20__ (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to _____________ (the “Employee”) a Performance Share Award (the “Award”) of ______ performance share units (the “Units”). The actual number of shares of Company common stock (the “Shares”) that may be issued under this Award will be determined in accordance with this Agreement by reference to the number of Units set forth above.

AbbVie Inc. – PRESS RELEASE (January 26th, 2018)

Reports Fourth-Quarter Diluted EPS of $0.03 on a GAAP Basis; Adjusted Diluted EPS of $1.48 Reflects Growth of 23.3 Percent Over Fourth-Quarter 2016

AbbVie Inc. – PRESS RELEASE (October 27th, 2017)

Third-Quarter Global HUMIRA Sales of $4.701 Billion Increased 15.8 Percent on a Reported Basis, or 14.8 Percent on an Operational Basis; Third-Quarter U.S. HUMIRA Sales of $3.151 Billion Increased 19.1 Percent

AbbVie Inc. – PRESS RELEASE (July 28th, 2017)

Second-Quarter Global Humira Sales of $4.716 Billion Increased 13.7 Percent on a Reported Basis, or 14.9 Percent on an Operational Basis; Second-Quarter U.S. Humira Sales of $3.201 Billion Increased 18.0 Percent

AbbVie Inc. – PERFORMANCE-VESTED RESTRICTED STOCK UNIT AGREEMENT (May 5th, 2017)

On this «Grant_Day» day of «Grant_Month», 2017 (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance-Vested Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”). The actual number of shares of Company common stock (the “Shares”) that may be issued under this Award will be determined in accordance with this Agreement by reference to the number of Units set forth above.

AbbVie Inc. – PERFORMANCE SHARE AWARD AGREEMENT (May 5th, 2017)

On this «Grant_Day» day of «Grant_Month», 2017 (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Share Award (the “Award”) of «NoShares12345» performance share units (the “Units”). The actual number of shares of Company common stock (the “Shares”) that may be issued under this Award will be determined in accordance with this Agreement by reference to the number of Units set forth above.

AbbVie Inc. – ABBVIE INC. NON-QUALIFIED STOCK OPTION AGREEMENT (May 5th, 2017)

On this «Grant_Day» day of «Grant_Month», 201__ (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name» (the “Employee”) an Option (the “Option”) to purchase a total of «NQSOs» Shares, at the price of $«Option_Price» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Market Value of the Shares on the Grant Date.

AbbVie Inc. – ABBVIE INC. NON-EMPLOYEE DIRECTOR RESTRICTED STOCK UNIT AGREEMENT (May 5th, 2017)

On this «Grant_Day» day of «Grant_Month», 201__ (the “Grant Date”), AbbVie Inc. (the “Company”) hereby grants to «First Name» «MI» «Last Name» (the “Director”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on a specified Delivery Date.

AbbVie Inc. – PRESS RELEASE (April 27th, 2017)

First-Quarter Global Humira Sales of $4.118 Billion Increased 15.1 Percent on a Reported Basis, or 15.8 Percent on an Operational Basis; First-Quarter U.S. Humira Sales of $2.696 Billion Increased 22.8 Percent

AbbVie Inc. – ABBVIE SUPPLEMENTAL PENSION PLAN (Amended and Restated Effective as of January 1, 2016) (February 17th, 2017)

1-1.    The Board of Directors of AbbVie Inc. (“AbbVie”) adopted this AbbVie Supplemental Pension Plan (the “Supplemental Plan” or “Plan”) effective as of January 1, 2013. The Plan provides for payment of (a) pension benefits calculated under the AbbVie Pension Plan (the “Pension Plan”) in excess of those which may be paid under that plan under the limits imposed by Section 415 of the U.S. Internal Revenue Code, as amended (the “Code”), and the Employee Retirement Income Security Act, as amended (“ERISA”), and (b) the additional pension benefits that would be payable under the Pension Plan if deferred awards under certain AbbVie non-qualified deferred compensation plans were included in “final earnings” as defined in the Pension Plan. The Plan is hereby amended and restated effective as of January 1, 2016.

AbbVie Inc. – ABBVIE DEFERRED COMPENSATION PLAN (February 17th, 2017)
AbbVie Inc. – PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results (January 27th, 2017)

·                 Delivers Full-Year Net Revenues of $25.638 Billion on a GAAP Basis; Adjusted Net Revenues of $25.560 Billion Grew 13.3 Percent on an Operational Basis

AbbVie Inc. – ABBVIE INC. €1,400,000,000 0.375% Senior Notes due 2019 €1,450,000,000 1.375% Senior Notes due 2024 €750,000,000 2.125% Senior Notes due 2028 UNDERWRITING AGREEMENT (November 17th, 2016)
AbbVie Inc. – ISSUER PAYING AGENT TRANSFER AGENT REGISTRAR - AND - TRUSTEE AGENCY AGREEMENT relating to Notes issued under a prospectus dated April 27, 2015, as supplemented by the prospectus supplement dated November 14, 2016 (November 17th, 2016)
AbbVie Inc. – ABBVIE INC. SUPPLEMENTAL INDENTURE NO. 4 €1,400,000,000 0.375% Senior Notes due 2019 €1,450,000,000 1.375% Senior Notes due 2024 €750,000,000 2.125% Senior Notes due 2028 (November 17th, 2016)

THIS SUPPLEMENTAL INDENTURE NO. 4, dated as of November 17, 2016 (the “Supplemental Indenture”), among ABBVIE INC., a Delaware corporation (the “Company”), U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”), Elavon Financial Services DAC, U.K. Branch, as paying agent (the “Paying Agent”) and Elavon Financial Services DAC, as transfer agent and registrar (the “Transfer Agent” and/or “Security Registrar”).

AbbVie Inc. – PRESS RELEASE AbbVie Reports Third-Quarter 2016 Financial Results (October 28th, 2016)

·                Reports Third-Quarter Diluted EPS of $0.97 on a GAAP Basis; Adjusted Diluted EPS of $1.21, Reflecting Growth of 7.1 Percent Over Third-Quarter 2015

AbbVie Inc. – PRESS RELEASE AbbVie Reports Second-Quarter 2016 Financial Results (July 29th, 2016)

·    Reports Second-Quarter Diluted EPS of $0.98 on GAAP Basis; Adjusted Diluted EPS of $1.26, Reflecting Growth of 16.7 Percent Over Second-Quarter 2015

AbbVie Inc. – STEM CENTRX, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 3, 2011 APPROVED BY THE STOCKHOLDERS: MARCH 3, 2011 TERMINATION DATE: MARCH 2, 2021 AMENDED AND RESTATED THROUGH JULY 28, 2015 (June 16th, 2016)